New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity

Mohamad Mohty, Andrea Bacigalupo, Faouzi Saliba, Andreas Zuckermann, Emmanuel Morelon, Yvon Lebranchu, Mohamad Mohty, Andrea Bacigalupo, Faouzi Saliba, Andreas Zuckermann, Emmanuel Morelon, Yvon Lebranchu

Abstract

In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin(®) was first licensed, its use in solid organ transplantation and hematology has expanded progressively. Although the evidence base is incomplete, specific roles for rATG in organ transplant recipients using contemporary dosing strategies are now relatively well-identified. The addition of rATG induction to a standard triple or dual regimen reduces acute cellular rejection, and possibly humoral rejection. It is an appropriate first choice in patients with moderate or high immunological risk, and may be used in low-risk patients receiving a calcineurin inhibitor (CNI)-sparing regimen from time of transplant, or if early steroid withdrawal is planned. Kidney transplant patients at risk of delayed graft function may also benefit from the use of rATG to facilitate delayed CNI introduction. In hematopoietic stem cell transplantation, rATG has become an important component of conventional myeloablative conditioning regimens, following demonstration of reduced acute and chronic graft-versus-host disease. More recently, a role for rATG has also been established in reduced-intensity conditioning regimens. In autoimmunity, rATG contributes to the treatment of severe aplastic anemia, and has been incorporated in autograft projects for the management of conditions such as multiple sclerosis, Crohn's disease, and systemic sclerosis. Finally, research is underway for the induction of tolerance exploiting the ability of rATG to induce immunosuppresive cells such as regulatory T-cells. Despite its long history, rATG remains a key component of the immunosuppressive armamentarium, and its complex immunological properties indicate that its use will expand to a wider range of disease conditions in the future.

Figures

Fig. 1
Fig. 1
rATG (Thymoglobulin®) dose in clinical studies according to year of publication with (a) standard triple maintenance regimen [, , –34]; (b) steroid-sparing regimen [–46] and (c) CNI-sparing regimen [, , –56]. Doses shown are protocol specified or, if unavailable, mean dose administered. CNI calcineurin inhibitor, rATG rabbit antithymocyte globulin
Fig. 2
Fig. 2
Chronic GvHD in patients with hematological malignancy undergoing unrelated HSCT randomized to rATG or no rATG [221]. GvHD graft-versus-host disease, HSCT hematopoietic stem cell transplantation, rATG rabbit antithymocyte globulin
Fig. 3
Fig. 3
Five-year outcomes from a randomized trial of patients with hematologic malignancies receiving reduced-intensity conditioning with fludarabine and either rATG (2.5 mg/kg) with busulfan (n = 69) or total body irradiation (n = 70) prior to HSCT from an HLA-identical sibling [236]. HLA human leukocyte antigen, HSCT hematopoietic stem cell transplantation, rATG rabbit antithymocyte globulin

References

    1. Organ Procurement and Transplant Network (OPTN) Annual Report 2011. . Accessed 14 Jan 2014.
    1. Cai J, Terasaki P. The current trend of induction and maintenance treatment in patients of different PRA levels: a report on OPTN/UNOS Kidney Transplant Registry data. Clin Transplant 2010;45–52.
    1. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs. 2010;70:691–732.
    1. Büchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transpl Immunol. 2013;28:120–126.
    1. Lindemans CA, Chiesa R, Amrolia PJ, Rao K, Nikolejava O, de Wildt A, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood. 2014;123:126–132.
    1. Morelon E, Lefrançois N, Besson C, Prévautel J, Brunet M, Touraine JL, et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol. 2010;23:53–58.
    1. Longuet H, Sautenet B, Gatault P, Thibault G, Barbet C, Marliere JF, et al. Risk factors for impaired CD4+ T-cell reconstitution following rabbit antithymocyte globulin treatment in kidney transplantation. Transpl Int. 2014;27(3):271–9. doi:10.1111/tri.12249.
    1. Thiyagarajan UM, Ponnuswamy A, Bagul A. Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol. 2013;37:586–601.
    1. Mourad G, Morelon E, Noël C, Glotz D, Lebranchu Y. The role of Thymoglobulin induction in kidney transplantation: an update. Clin Transplant. 2012;26:E450–E464.
    1. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs. 2009;69:1483–1512.
    1. Popow I, Leitner J, Grabmeier-Pfistershammer K, Majdic O, Zlabinger GJ, Kundi M, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transplant. 2013;13:3103–3113.
    1. Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, et al. Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. Pharmacogenet Genomics. 2014;24:26–34.
    1. Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998;66:29–37.
    1. Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int. 1998;11:231–236.
    1. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67:1011–1018.
    1. Mourad G, Garrigue V, Squifflet JP, Besse T, Berthoux F, Alamartine E, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation. 2001;72:1050–1055.
    1. Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation. 2003;75:844–851.
    1. Schnetzler B, Leger P, Völp A, Dorent R, Pavie A, Gandjbakhch I. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients. Transpl Int. 2002;15:317–325.
    1. Agha IA, Rueda J, Alvarez A, Singer GG, Miller BW, Flavin K, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation. 2002;73:473–475.
    1. Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation. 2003;76:798–802.
    1. Wong W, Agrawal N, Pascual M, Anderson DC, Hirsch HH, Fujimoto K, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int. 2006;19:629–635.
    1. Stevens RB, Mercer DF, Grant WJ, Freifeld AG, Lane JT, Groggel GC, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation. 2008;82:1391–1399.
    1. Djamali A, Turc-Baron C, Portales P, Leverson G, Chong G, Clot J, et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation. 2000;69:799–805.
    1. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967–1977.
    1. Zaltzman JS, Paul LC. Single center experience with thymoglobulin in renal transplantation. Transplant Proc. 1997;29:27S–28S.
    1. Büchler M, Hurault de Ligny B, Madec C, Lebranchu Y, French Thymoglobuline Pharmacovigilance Study Group Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant. 2003;17:539–545.
    1. Guttmann RD, Flemming C. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin. Clin Transplant. 1997;11:185–192.
    1. Haririan A, Morawski K, Sillix DH, El-Amm JM, Garnick J, West MS, et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation. 2005;79:716–721.
    1. Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant. 1998;13:711–715.
    1. Rostaing L, Lavayssière L, Kamar N. Hematologic adverse effects of 2 different polyclonal antilymphocyte preparations in de novo kidney transplant patients. Exp Clin Transplant. 2010;8:178–180.
    1. Kim JM, Jang HR, Ko JS, Kwon CH, Kwak MS, Hur WS, et al. Comparison between thymoglobulin and ATGAM as an induction agent in adult kidney transplantation: a single-center experience. Transplant Proc. 2012;44:171–174.
    1. Brokhof MM, Sollinger HW, Hager DR, Muth BL, Pirsch JD, Fernandez LA, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation. 2014;97:612–617.
    1. LaMattina JC, Mezrich JD, Hofmann RM, Foley DP, D’Alessandro AM, Sollinger HW, et al. Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int. 2012;25:518–526.
    1. Requião-Moura LR, Ferraz E, Matos AC, Tonato EJ, Ozaki KS, Durão MS, et al. Comparison of long-term effect of thymoglobulin treatment in patients with a high risk of delayed graft function. Transplant Proc. 2012;44:2428–2433.
    1. Libório AB, Mendoza TR, Esmeraldo RM, Oliveira ML, Paes FJ, Silva Junior GB, et al. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin. Int Immunopharmacol. 2011;11:1832–1836.
    1. Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients–an interim analysis. Am J Transplant. 2005;5:1529–1536.
    1. Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation. 2001;71:1089–1090.
    1. Khwaja K, Asolati M, Harmon JV, Melancon JK, Dunn TB, Gillingham KJ, et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation. 2004;78:1397–1399.
    1. Matas AJ, Kandaswamy R, Gillingham KJ, McHugh L, Ibrahim H, Kasiske B, et al. Prednisone-free maintenance immunosuppression: a 5-year experience. Am J Transplant. 2005;5:2473–2478.
    1. Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc. 2006;38:1307–1313.
    1. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–577.
    1. Gruber SA, West MS, Sillix DH, El-Amm JM, Garnick J, Morawski K, et al. Preliminary results with early corticosteroid withdrawal in African American renal allograft recipients. Surgery. 2005;138:772–778.
    1. Haririan A, Sillix DH, Morawski K, El-Amm JM, Garnick J, Doshi MD, et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant. 2006;6:2396–2402.
    1. Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and Cell Cept-based calcineurin inhibitor-minimization protocol. Clin Transplant. 2007;21:101–109.
    1. Matas AJ, Ramcharan T, Paraskevas S, Gillingham KJ, Dunn DL, Gruessner RW, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant. 2001;1:278–283.
    1. Rajab A, Pelletier RP, Henry ML, Ferguson RM. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant. 2006;20:537–546.
    1. Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002;2:48–56.
    1. Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation. 2010;89:1511–1517.
    1. Büchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, et al. SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant. 2007;7:2522–2531.
    1. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006;6:514–522.
    1. Lo A, Egidi MF, Gaber LW, Amiri HS, Vera S, Nezakatgoo N, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation. 2004;77:1228–1235.
    1. Grinyó JM, Gil-Vernet S, Seron D, Hueso M, Fulladosa X, Cruzado JM, et al. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Nephrol Dial Transplant. 1998;13:2061–2064.
    1. Alexander JW, Goodman HR, Cardi M, Austin J, Goel S, Safdar S, et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int. 2006;19:295–302.
    1. Cantarovich D, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Lerat L, et al. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation. Nephrol Dial Transplant. 2000;15:1673–1676.
    1. Shaffer D, Langone A, Nylander WA, Goral S, Kizilisik AT, Helderman JH. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant. 2003;17(Suppl 9):31–34.
    1. Wang CJ, Tuffaha A, Zhang D, Diederich DA, Wetmore JB. A CD3+ count-based thymoglobulin induction regimen permits delayed introduction of calcineurin inhibitors in kidney transplantation. Clin Transplant. 2012;26:900–909.
    1. Laftavi MR, Patel S, Soliman MR, Alnimri M, Kohli R, Said M, et al. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Transplant Proc. 2011;43:466–468.
    1. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE., Jr Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation. 2003;75:1396–1399.
    1. Grafals M, Simpson M, Gilligan H, Pomposelli J, Akoad M, Kwaja K, et al. Prospective randomized study of low dose antithymocyte globulin as induction in non sensitized adult renal transplant recipients [abstract no. 1351]. Am J Transplant. 2013;13 Suppl 5.
    1. Popat R, Syed A, Puliatti C, Cacciola R. Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants. Transplantation. 2014;97:1161–1165.
    1. Patel S, Pankewycz O, Kohli R, Said M, Alnimri M, Feng L, et al. Obesity in renal transplantation: the role of induction therapy on long-term outcomes. Transplant Proc. 2011;43:469–471.
    1. Schenker P, Ozturk A, Vonend O, Krüger B, Jazra M, Wunsch A, et al. Single-dose thymoglobulin induction in living-donor renal transplantation. Ann Transplant. 2011;16:50–58.
    1. De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, et al. Preliminary results of a “prope” tolerogenic regimen with thymoglobulin pre-treatment and hepatitis C virus recurrence in liver transplantation. Transplantation. 2005;80:8–12.
    1. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3 + lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002;73:1514–1518.
    1. Koch A, Daniel V, Dengler TJ, Schnabel PA, Hagl S, Sack FU. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat) J Heart Lung Transplant. 2005;24:708–713.
    1. Tsapepas D, Mohan S, Crew RJ, Cohen D, Ratner LE. Small thymoglobulin dose adjustments have profound impact on early rejections in renal transplantation [abstract no. 389]. Am J Transplant 2011;11 Suppl 2.
    1. Khanmoradi K, Knorr JP, Feyssa EL, Parsikia A, Jawa P, Dinh H-B, et al. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients. Exp Clin Transplant. 2013;11:222–228.
    1. Gaber AO, Matas AJ, Henry ML, Brennan DC, Stevens RB, Kapur S, et al. Thymoglobulin Antibody Immunosuppression in Living Donor Recipients Investigators. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation. 2012;94:331–337.
    1. Kho MM, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W. The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012;26:186–190.
    1. Préville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation. 2001;71:460–468.
    1. Soliman T, Hetz H, Burghuber C, Gyöi G, Silberhumer G, Steininger R, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transplantation. 2007;13:1039–1044.
    1. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation. 2004;78:584–590.
    1. Rostaing L, Saliba F, Calmus Y, Dharancy S, Boillot O. Review article: use of induction therapy in liver transplantation. Transplant Rev (Orlando) 2012;26:246–260.
    1. Mattei M, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant. 2007;26:693–699.
    1. Flaman F, Zieroth S, Rao V, Ross H, Delgado DH. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant. 2006;25:1358–1362.
    1. Carlsen J, Johansen M, Boesgaard S, Andersen CB, Arendrup H, Aldershvilet J, et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant. 2005;24:296–302.
    1. Aliabadi A, Grömmer M, Cochrane A, Salameh O, Zuckermann A. Induction therapy in heart transplantation: where are we now? Transpl Int. 2013;26:684–695.
    1. Goland S, Lawrence S, Czer C, De Robertis MA, Mirocha J, Zivari K, et al. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates. J Heart Lung Transplant. 2008;27:1115–1121.
    1. Krasinskas AM, Kreisel D, Acker MA, Bavaria JE, Pochettino A, Kotloff RM, et al. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation. 2002;73:1339–1341.
    1. Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, Brennan DC. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation. 2005;80:41–46.
    1. Walther S, Beiras-Fernandez A, Csapo C, Münzing S, Stief CG, Hammer C, et al. Influence of polyclonal antithymocyte globulins on the expression of adhesion molecules of isolated human umbilical vein endothelial cells. Transplantation Proc. 2010;42:1931–1934.
    1. Beiras-Fernandez A, Chappell D, Hammer C, Beiras A, Reichart B, Thein E. Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. Transpl Immunol. 2009;20:224–228.
    1. Beiras-Fernandez A, Thein E, Chappell D, Gallego R, Fernandez-Roel D, Kemming G, et al. Polyclonal anti-thymocyte globulins influence apoptosis in reperfused tissues after ischemia in a non-human primate model. Transpl Int. 2004;17:453–457.
    1. Hardinger KL, Rasu RS, Skelton R, Miller BW, Brennan DC. Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? J Transplant. 2010;2010:957549.
    1. Marfo K, Akalin E, Wang C, Lu A. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients. Am J Health Syst Pharm. 2011;68:2276–2282.
    1. Uber WE, Uber LA, VanBakel AB, Crumbley AJ, 3rd, Pereira NL, Ikonomidis JS, et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc. 2004;36:3245–3249.
    1. Bunnapradist S, Takemoto SK. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc. 2005;37:889–891.
    1. Lebranchu Y, Baan C, Biancone L, Legendre C, Morales JM, Naesens M, et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int. 2014;27:129–138.
    1. Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol. 2012;23:2061–2071.
    1. Burns JM, Cornell LD, Perry DK, Pollinger HS, Gloor JM, Kremers WK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant. 2008;8:2684–2694.
    1. Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009;20:1385–1392.
    1. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005;80:457–465.
    1. Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant. 2008;23:2024–2032.
    1. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC. TRIMS Study Investigators. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. Clin Transplant. 2009;24:73–83.
    1. Tian JH, Wang X, Yang KH, Liu AP, Luo XF, Zhang J. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. Transplant Proc. 2009;41:3671–3676.
    1. Morgan RD, O’Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation. 2012;93:1179–1188.
    1. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364:1909–1919.
    1. Rodríguz-Reimundes E, Buron F, Chauvet C, Daoud S, Thaunat O, Brunet M, et al. Retreatment by antithymocyte globulin for second kidney transplantation:efficacy, tolerance and safety. Transpl Immunol. 2013;28:6–8.
    1. Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation. 2005;79:958–963.
    1. Colleen Hastings M, Wyatt RJ, Lau KK, Jones DP, Powell SL, Hays DW, et al. Five years’ experience with thymoglobulin induction in a pediatric renal transplant population. Pediatr Transplant. 2006;10:805–810.
    1. Schwartz JJ, Ishitani MB, Weckwerth J, Morgenstern B, Milliner D, Stegall MD. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. Transplantation. 2007;84:715–721.
    1. Brophy PD, Thomas SE, McBryde KD, Bunchman TE. Comparison of polyclonal induction agents in pediatric renal transplantation. Pediatr Transplant. 2001;5:174–178.
    1. Kamel MH, Mohan P, Little DM, Awan A, Hickey DP. Rabbit antithymocyte globulin as induction immunotherapy for pediatric deceased donor kidney transplantation. J Urol. 2005;174:703–707.
    1. Hardinger KL, Schnitzler MA, Koch MJ, Labile E, Stirnemann PM, Miller B, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation. 2006;81:1285–1289.
    1. Martins L, Fonseca I, Almeida M, Henriques AC, Dias L, Sarmento AM, et al. Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival. Transplant Proc. 2005;37:2755–2758.
    1. Abouna GM, Kumar MS, Stephan R, Prior JE, Lyons P, Bulova SI, et al. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation. Transplant Proc. 1993;25:2241–2242.
    1. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81:1227–1233.
    1. Willoughby LM, Schnitzler MA, Brennan DC, Pinsky BW, Dzebisashvili N, Buchanan PM, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation. 2009;87:1520–1529.
    1. Kuo HT, Huang E, Emami S, Pham PT, Wilkinson AH, Danovitch GM, et al. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients. Transplantation. 2012;93:493–502.
    1. Oweis A, Zaltzman J, Kim J. Comparative effectiveness of rabbit anti-thymocyte globulin vs. interleukin-2 receptor blockers in deceased donor kidney transplants with delayed graft function. Am J Transplant 2013;13(Suppl 5):Abstract 173.
    1. Bogetti D, Sankary HN, Jarzembowski TM, Manzelli A, Knight PS, Thielke J, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant. 2005;19:507–511.
    1. Harrison JJ, Hamandi B, Li Y, Famure O, Kim SJ. Timing of rabbit antithymocyte globulin induction therapy in kidney transplantation: an observational cohort study. Transplant Res. 2014;3:1.
    1. Mehrabi A, Mood ZhA, Sadeghi M, Schmied BM, Müller SA, Welsch T, et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant. 2007;22(Suppl 8):viii54–viii60.
    1. Chapal M, Le Borgne F, Legendre C, Kreis H, Mourad G, Garrigue V, et al. The DGFS: a useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors. Kidney Int 2014. doi:10.1038/ki.2014.188.
    1. Lebranchu Y, Aubert P, Bayle F, Bedrossian J, Berthoux F, Bourbigot B, et al. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study Group. Transplant Proc. 2000;32:396–397.
    1. Chavers BM, Chang YC, Gillingham KJ, Matas A. Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. Transplantation. 2009;88:237–241.
    1. Li L, Chaudhuri A, Chen A, Zhao X, Bezchinsky M, Concepcion W, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation. 2010;90:1516–1520.
    1. Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, et al. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. Pharmacotherapy. 2011;31:566–573.
    1. Swanson SJ, Hale DA, Mannon RB, Kleiner DE, Cendales LC, Chamberlain CE, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet. 2002;360:1662–1664.
    1. Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int. 2003;16:820–827.
    1. Lebranchu Y, Snanoudj R, Toupance O, Weestel PF, Hurault de Ligny B, Buchler M, et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study. Am J Transplant. 2012;12:1801–1810.
    1. Venot M, Abboud I, Duboust A, Michel C, Suberbielle C, Vérine J, et al. Calcineurin inhibitor-free monotherapy in human leukocyte antigen-identical live donor renal transplantation. Transplantation. 2011;91:330–333.
    1. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-75.
    1. Flechner SM, Glyda M, Cockfield S, Grinyó J, Legendre Ch, Russ G, et al. The ORION Study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011;11:1633–1644.
    1. Favi E, Spagnoletti G, Silvestrini N, Salerno MP, Pedroso JA, Romagnoli J, et al. Thymoglobulin plus basiliximab versus basiliximab induction in deceased donor kidney transplant recipients treated with tacrolimus and MMF: 1-year results of a prospective clinical trial. Transpl Int. 2013;26 Suppl s2:83.
    1. Ferguson R, Grinyó J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11:66–76.
    1. Bouvy A, Klepper M, Kho M, Ijzermans J, Litjens N, Betjes M, et al. Rabbit antithymocyte globulin induction therapy induces donor-specific helios−FOXP3+ regulatory T cells in kidney transplant patients [abstract no. 237]. Am J Transplant. 2013;13 Suppl.
    1. Todeschini M, Cortinovis M, Perico N, Poli F, Innocente A, Cavinato RA, et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol. 2013;191:2818–2828.
    1. Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Willingham DL, et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation. 2009;87:227–232.
    1. Kubal CA, Mangus RS, Saxena R, Lobashevsky A, Higgins N, Agarwal A, et al. Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation. 2014;97:56–63.
    1. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation. 2011;91:1103–1109.
    1. Huang Y, Ramon D, Luan FL, Sung R, Samaniego M. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation. Clin Transplant. 2012;247–56.
    1. Loupy AD, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–1226.
    1. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010;90:1511–1515.
    1. Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant. 2010;10:590–601.
    1. Mangus R, Fridell AJ, Vianna RM, Kwo PY, Chen J, Tector AJ. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl. 2012;18:786–795.
    1. Boillot O, Seket B, Dumortier J, Pittau G, Boucaud C, Bouffard Y, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl. 2009;15:1426–1434.
    1. Horton PJ, Tchervenkov J, Barkun JS, Rochon C, Chaudhury PK, Znajda TL, et al. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients. J Gastrointest Surg. 2005;9:896–902.
    1. Tchervenkov J, Flemming C, Guttmann RD, Des Gachons G. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. Transplant Proc. 1997;29(Suppl 7A):13S–15S.
    1. Halldorson J, Bakthavatsalam B, Dick A, Rayhill S, Perkins J, Reyes J. Antithymocyte globulin induction is associated with improved graft survival and reduced ischemic cholangiopathy after DCD liver transplantation as compared to basiliximab [abstract no. 265]. Am J Transplant. 2013;13 Suppl 5.
    1. Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl. 2004;10:404–407.
    1. Varo E, López A, Rivero C. Initial immunosuppression in liver transplant recipients with impaired renal function. Transplant Proc. 2005;37:3909–3912.
    1. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol. 1997;92:1453–1457.
    1. Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 2011;24:640–650.
    1. Nair S, Lipscomb J, Eason J. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Transplantation. 2008;86:418–422.
    1. Kamar N, Ribes D, Sandres-Saune K, Suc B, Barange K, Cointault O, et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. Transplant Proc. 2004;36:2757–2761.
    1. Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant. 2008;22:76–81.
    1. Carrier M, Leblanc MH, Perrault LP, White M, Doyle D, Beaudoin D, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. Heart Lung Transplant. 2007;26:258–263.
    1. Chou NK, Wang SS, Chen YS, Yu HY, Chi NH, Wang CH, et al. Induction immunosuppression with basiliximab in heart transplantation. Transplant Proc. 2008;40:2623–2625.
    1. Eisen HJ, Kobashigawa J, Starling RC, Pauly DR, Kfoury A, Ross H, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant. 2013;13:1203–1216.
    1. Baran DA, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. Task Force 2: immunosuppression and rejection. ISHLT; 2010: pp. 1–41.
    1. Delgado DH, Miriuka SG, Cusimano RJ, Feindel C, Rao V, Ross HJ. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant. 2005;24:166–169.
    1. Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation. 2004;78:779–781.
    1. Fuchs U, Zittermann A, Amini A, Ensminger SM, Gummert JF, Schulz U. Clinical outcome in heart transplant recipients with chronic kidney disease receiving Thymoglobulin for induction therapy. German Transplant Society (DTG) Congress 2013.
    1. Singh TP, Faber C, Blume ED, Worley S, Almond CS, Smoot LB, et al. Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients. J Heart Lung Transplant. 2010;29:517–522.
    1. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation. 2008;117:2131–2141.
    1. Zuckermann A, Ploner M, Czerny M, Keziban U, Birsan T, Laufer G, et al. Low incidence of graft arteriosclerosis after cardiac transplantation: risk factor analysis for patients with induction therapy. Transplant Proc. 2002;34:1869–1871.
    1. Bonaros N, Dunkler D, Kocher A, Imhof M, Grimm M, Zuckermann A, et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. J Heart Lung Transplant. 2006;25:1154–1163.
    1. Carrier M, White M, Perrault LP, Pelletier GB, Pellerin M, Robitaille D, et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant. 1999;18:1218–1223.
    1. Faggian G, Forni A, Milano AD, Chiominto B, Walpoth BH, Scarabelli T, et al. Antithymocyte globulin induction therapy in heart transplantation: prospective randomized study of high vs standard dosage. Transplant Proc. 2010;42:3679–3687.
    1. Zhang R, Haverich A, Strüber M, Simon A, Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant. 2008;27:603–609.
    1. Sweet SC. Induction therapy in lung transplantation. Transplant Int. 2013;26:696–703.
    1. Hayes D., Jr A review of bronchiolitis obliterans syndrome and therapeutic strategies. J Cardiothorac Surg. 2011;6:92.
    1. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest. 2011;140:502–508.
    1. Lease ED, Zaas DW. Update on infectious complications following lung transplantation. Curr Opin Pulm Med. 2011;17:206–209.
    1. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012;31:1073–1086.
    1. Hachem RR, Edwards LB, Yusen RD, Chakinala MM, Alexander Patterson G, Trulock EP. The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clin Transplant. 2008;22:603–608.
    1. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest. 1999;116:127–133.
    1. Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg. 2003;125:891–900.
    1. Hartwig MG, Snyder LD, Appel JZ, 3rd, Cantu E, 3rd, Lin SS, Palmer SM, et al. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant. 2008;27:547–553.
    1. Mullen JC, Oreopoulos A, Lien DC, Bentley MJ, Modry DL, Stewart K, et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant. 2007;26:504–510.
    1. Bazerbachi F, Selzner M, Boehnert MU, Marquez MA, Norgate A, McGilvray ID, et al. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation. 2011;92:1039–1043.
    1. Cantarovich D, Karam G, Giral-Classe M, Hourmant M, Dantal J, Blancho G, et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int. 1998;54:1351–1356.
    1. Cantarovich D, Papuchon E, Guillot-Guéguen C, Blancho G, Dantal J, Giral-Classe M, et al. CNI- and steroid-free immunosuppression after simultaneous pancreas-kidney transplantation: one-year results of a prospective and randomized study. Transpl Int. 2013;26 Suppl s2:172.
    1. Kaufman DB, Leventhal JR, Koffron AJ, Gallon LG, Parker MA, Fryer JP, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation. 2002;73:169–177.
    1. Fridell JA, Agarwal A, Powelson JA, Goggins WC, Milgrom M, Pescovitz MD, et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. Transplantation. 2006;82:389–392.
    1. Aoun M, Eschewege P, Hamoudi Y, Beaudreuil S, Duranteau J, Cheisson G, et al. Very early steroid withdrawal in simultaneous pancreas-kidney transplants. Nephrol Dial Transplant. 2007;22:899–905.
    1. Freise CE, Kang SM, Feng S, Posselt A, Hirose K, Hirose R, et al. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. Transplant Proc. 2004;36:1067–1068.
    1. Reddy KS, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, et al. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Transplant Proc. 2010;42:2006–2008.
    1. O’Connell PJ, Holmes-Walker DJ, Goodman D, Hawthorne WJ, Loudovaris T, Gunton JE, et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant. 2013;13:1850–1858.
    1. Jamiolkowski RM, Guo LY, Li YR, Shaffer SM, Naji A. Islet transplantation in type I diabetes mellitus. Yale J Biol Med. 2012;85:37–43.
    1. Cai J. Intestine and multivisceral transplantation in the United States: a report of 20-year national registry data (1990–2009). Clin Transplant. 2009;83–101.
    1. Wu G, Selvaggi G, Nishida S, Moon J, Island E, Ruiz P, et al. Graft-versus-host disease after intestinal and multivisceral transplantation. Transplantation. 2011;91:219–224.
    1. Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation. 2008;85:1290–1293.
    1. Trevizol AP, David AI, Dias ER, Mantovani D, Pécora R, D’Albuquerque LA. Intestinal and multivisceral transplantation immunosuppression protocols: literature review. Transplant Proc. 2012;44:2445–2448.
    1. Abu-Elmagd KM, Costa G, Bond GJ, Wu T, Murase N, Zeevi A, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int. 2009;22:96–109.
    1. Abu-Elmagd KM, Costa G, Bond GJ, Soltys K, Martin L, Koritsky DA, et al. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. Clin Transplant. 2012:155–66.
    1. Diaz-Siso JR, Bueno EM, Sisk GC, Marty FM, Pomahac B, Tullius SG. Vascularized composite tissue allotransplantation: state of the art. Clin Transplant. 2013;27:330–337.
    1. Murphy BD, Zuker RM, Borschel GH. Vascularized composite allotransplantation: an update on medical and surgical progress and remaining challenges. J Plast Reconstr Aesthet Surg. 2013;66:1449–1455.
    1. Devauchelle B, Badet L, Lengelé B, Morelon E, Testelin S, Michallet M, et al. First human face allograft: early report. Lancet. 2006;368:203–209.
    1. Petruzzo P, Testelin S, Kanitakis J, Badet L, Lengelé B, Girbon JP, et al. First human face transplantation: 5 years outcomes. Transplantation. 2012;93:236–240.
    1. Siemionow MZ, Papay F, Djohan R, Bernard S, Gordon CR, Alam D, et al. First U.S. near-total human face transplantation: a paradigm shift for massive complex injuries. Plast Reconstr Surg. 2010;125:111–122.
    1. Barret JP, Gavaldà J, Bueno J, Nuvials X, Pont T, Masnou N, et al. Full face transplant: the first case report. Ann Surg. 2011;254:252–256.
    1. Dubernard JM, Owen E, Herzberg G, Lanzetta M, Martin X, Kapila H, et al. Human hand allograft: report on first 6 months. Lancet. 1999;353:1315–1320.
    1. Schneeberger S, Gorantla VS, van Riet RP, Lanzetta M, Vereecken P, van Holder C, et al. Atypical acute rejection after hand transplantation. Am J Transplant. 2008;8:688–696.
    1. Morelon E, Kanitakis J, Petruzzo P. Immunological issues in clinical composite tissue allotransplantation: where do we stand today? Transplantation. 2012;93:855–859.
    1. Engels EA, Pfeiffer RM, Fraumeni JF, Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–1901.
    1. Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–2625.
    1. Caillard S, Lamy FX, Quelen C, Dantal J, Lebranchu Y, Lang P, et al. French Transplant Centers. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant. 2012;12:682–693.
    1. Opelz G, Döhler B. Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation. 2010;89:567–572.
    1. Emin A, Rogers C, Thekkudan J, Bonser RS, Banner NR. Steering Group, UK Cardiothoracic Transplant Audit. Antithymocyte globulin therapy for adult heart transplantation: a UK national study. J Heart Lung Transplant. 2011;30:770–777.
    1. Gajarski R, Blume E, Urschel S, Schechtman K, Zheng J, West LJ, et al. Pediatric Heart Transplant Study Investigators. Infection and malignancy after pediatric transplantation: the role of induction therapy. J Heart Lung Transplant. 2011;30:299–308.
    1. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4:87–93.
    1. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009;87:1019–1026.
    1. Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU. Treatment for BK virus: incidence, risk factors, and outcomes for kidney transplant recipients in the United States. Transpl Int. 2009;22:626–634.
    1. Lim WH, Turner RM, Chapman JR, Ma MK, Webster AC, Craig JC, et al. Acute rejection, T-cell-depleting antibodies, and cancer after transplantation. Transplantation. 2014;97:817–825.
    1. Snanoudj R, Legendre C. T-cell-depleting antibodies and risk of cancer after transplantation. Transplantation. 2014;97:808–809.
    1. Marks WH, Ilsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc. 2011;43:1395–1404.
    1. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–230.
    1. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80:1233–1243.
    1. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of and induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76:1289–1293.
    1. Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant. 2005;9:622–626.
    1. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation. 2005;80:193–197.
    1. Dadhania D, Snopkowski C, Ding R, Muthukumar T, Chang C, Aull M, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation. 2008;86:521–528.
    1. Borni-Duval C, Caillard S, Olagne J, Perrin P, Braun-Parvez L, Heibel F, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation. 2013;95:1498–1505.
    1. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87:621–630.
    1. Acott P, Babel N. BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? Ann Transplant. 2012;17:86–99.
    1. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48:772–786.
    1. Remberger M, Svahn BM, Hentschke P, Löfgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:823–830.
    1. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) Blood. 2001;98:2942–2947.
    1. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–565.
    1. Duggan P, Booth K, Chaudhry A, Stewart D, Ruether JD, Glück S, et al. Unrelated donor BMT recipients given pretransplant low dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant. 2002;30:681–686.
    1. Remberger M, Storer B, Ringdén O, Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant. 2002;29:391–397.
    1. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12:573–584.
    1. Call SK, Kasow KA, Barfield R, Madden R, Leung W, Horwitz E, et al. Total and active rabbit antithymocyte globulin (rATG; Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15:274–278.
    1. Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant. 2007;13:299–306.
    1. Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR, et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant. 2008;14:888–895.
    1. Galambrun C, Pondarré C, Bertrand Y, Loundou A, Bordigoni P, Frange P, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transpl. 2013;9:62–68.
    1. Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A, et al. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1734–1744.
    1. Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007;2:75–91.
    1. Mohty M, Gaugler B. Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. Best Pract Res Clin Haematol. 2010;23:275–82.
    1. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versus- host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102:470–476.
    1. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353:1321–1331.
    1. Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, et al. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma. 2012;53:915–919.
    1. Remberger M, Ringdén O, Hägglund H, Svahn BM, Ljungman P, Uhlin M, et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant. 2013;27:E368–E374.
    1. Blaise D, Tabrizi R, Boher JM, Le Corroller-Soriano AG, Bay JO, Fegueux N, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer. 2013;119:602–611.
    1. Horn B, Baxter-Lower LA, Englert L, McMillan A, Quinn M, Desantes K, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant. 2006;37:263–269.
    1. Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F, et al. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamil transferase, donor type and cell dose. Bone Marrow Transplant. 2003;32:205–211.
    1. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J, et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day + 7 after alternative donor transplants. Bone Marrow Transplant. 2010;45:385–391.
    1. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107:4177–4181.
    1. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:655–668.
    1. Van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and qualitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98:972–978.
    1. Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 2012;47:101–106.
    1. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109:4582–4585.
    1. Bacigalupo A, Socié G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M, et al. Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97:1142–1148.
    1. Bacigalupo A, Socie’ G, Lanino E, Prete A, Locatelli F, Locasciulli A, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010;95:976–982.
    1. Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK, et al. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: a phase II prospective multicenter study. Biol Blood Marrow Transplant. 2010;16:1582–1588.
    1. Korthof ET, Békássy AN, Hussein AA. Management of acquired aplastic anemia in children. Bone Marrow Transplant. 2013;48:191–195.
    1. European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party. Rabbit ATG for aplastic anaemia treatment: a backward step? Lancet. 2011;378:1831–1833.
    1. Afable MG, 2nd, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H, et al. Efficacy of rabbit antithymocyte globulin in severe aplastic anemia. Haematologica. 2011;96:1269–1275.
    1. Atta EA, Dias DS, Marra VLN, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2010;89:851–859.
    1. Halkes CJM, Brand A, von dem Borne PA, Marijt EW, Willemze R, Veelken J, et al. Increasing the dose of rabbit-ATG does not lead to a higher response rate in the first-line treatment of severe aplastic anaemia. Bone Marrow Transplant. 2011;46(1 Suppl):S373.
    1. Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119:5391–5396.
    1. Sakamoto T, Obara N, Kurita N, Sakata-Yanagimoto M, Nishikii H, Yokoyama Y, et al. Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia. Int J Hematol. 2013;98:319–322.
    1. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430–438.
    1. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. EBMT Autoimmune Disease Working Party (ADWP); Paediatric Diseases Working Party (PDWP). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47:770–790.
    1. Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, et al. European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; HSCT in MS International Study Group. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18:825–834.
    1. Strober S. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Blood Cells Mol Dis. 2008;40:48–54.
    1. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358:362–368.
    1. Scandling JD, Busqueb S, Dejbakhsh-Jones S, Beniked C, Sarwale M, Millanb MT, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012;12:1133–1145.
    1. Libetta A, Canevari M, Margiotta E, Martinelli C, Borettaz I, Esposito P, et al. Preliminary data of controlled randomised study (EVER TWIST) on tolerance induction. Transpl Int. 2011;26(Suppl 2):20.
    1. Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502–1510.
    1. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358:353–361.
    1. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573–1579.
    1. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568–1576.
    1. Thomas HR, Gitelman SE. Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr Diab. 2013;14:311–321.
    1. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, et al. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012;157:312–320.
    1. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, et al. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009;23:1297–1302.
    1. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 2006;54:3750–3760.
    1. Lytton SD, Denton CP, Nutzenberger AM. Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action. Ann N Y Acad Sci. 2007;1110:285–296.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다